Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 79Squamous Cell Carcinoma of Head and Neck 44Lung Neoplasms 36Urinary Bladder Neoplasms 22Oropharyngeal Neoplasms 22Head and Neck Neoplasms 19Nasopharyngeal Carcinoma 18Carcinoma 16Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14Esophageal Squamous Cell Carcinoma 14Uterine Cervical Neoplasms 13Neoplasms 13Neoplasm Metastasis 13Cholangiocarcinoma 13Ovarian Neoplasms 12Colorectal Neoplasms 12Pancreatic Neoplasms 11Carcinoma, Squamous Cell 11Laryngeal Neoplasms 10Stomach Neoplasms 9Mouth Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Mesothelioma, Malignant 6

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Cisplatin × 90 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡